Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification

Sasha S Bjergfelt, Ida M H Sørensen, Henrik Ø Hjortkjær, Nino Landler, Ellen L F Ballegaard, Tor Biering-Sørensen, Klaus F Kofoed, Theis Lange, Bo Feldt-Rasmussen, Henrik Sillesen, Christina Christoffersen, Susanne Bro, Sasha S Bjergfelt, Ida M H Sørensen, Henrik Ø Hjortkjær, Nino Landler, Ellen L F Ballegaard, Tor Biering-Sørensen, Klaus F Kofoed, Theis Lange, Bo Feldt-Rasmussen, Henrik Sillesen, Christina Christoffersen, Susanne Bro

Abstract

Background: Chronic kidney disease accelerates both atherosclerosis and arterial calcification. The aim of the present study was to explore whether maximal carotid plaque thickness (cPTmax) was increased in patients with chronic kidney disease compared to controls and associated with cardiovascular disease and severity of calcification in the carotid and coronary arteries.

Methods: The study group consisted of 200 patients with chronic kidney disease stage 3 from the Copenhagen Chronic Kidney Disease Cohort and 121 age- and sex-matched controls. cPTmax was assessed by ultrasound and arterial calcification by computed tomography scanning.

Results: Carotid plaques were present in 58% of patients (n = 115) compared with 40% of controls (n = 48), p = 0.002. Among participants with plaques, cPTmax (median, interquartile range) was significantly higher in patients compared with controls (1.9 (1.4-2.3) versus 1.5 (1.2-1.8) mm), p = 0.001. Cardiovascular disease was present in 9% of patients without plaques (n = 85), 23% of patients with cPTmax 1.0-1.9 mm (n = 69) and 35% of patients with cPTmax >1.9 mm (n = 46), p = 0.001. Carotid and coronary calcium scores >400 were present in 0% and 4%, respectively, of patients with no carotid plaques, in 19% and 24% of patients with cPTmax 1.0-1.9 mm, and in 48% and 53% of patients with cPTmax >1.9 mm, p<0.001.

Conclusions: This is the first study showing that cPTmax is increased in patients with chronic kidney disease stage 3 compared to controls and closely associated with prevalent cardiovascular disease and severity of calcification in both the carotid and coronary arteries.

Conflict of interest statement

I have read the journal´s policy and the authors of this manuscript have the following competing interests: BFR reports research grants from The NovoNordisk Foundation (Steno Collaborative Grant), HS reports research grants from Philips Ultrasound and Bayer and honoraria from Bayer, Novo Nordisk, Bracco and Philips Ultrasound, TBS reports research grants from Sanofi Pasteur and GE Healthcare, the Lundbeck Foundation and the Novo Nordisk Foundation during the conduct of the study. All other authors: no competing interests.

Figures

Fig 1. Measurement of maximal carotid plaque…
Fig 1. Measurement of maximal carotid plaque thickness (cPTmax).
Image showing a segment of the carotid artery with a plaque, which is scanned with a transducer. The transverse section of the carotid artery shows how cPTmax is measured.
Fig 2. Distribution of maximal carotid plaque…
Fig 2. Distribution of maximal carotid plaque thickness (cPTmax) in patients with CKD stage 3 and controls.
Includes only participants with plaques (115/200 patients and 48/121 controls). Dot plot with median (long black horizonal line) and interquartiles (short black horizontal lines). The p-value is from a Mann-Whitney U-test.
Fig 3. Association between maximal carotid plaque…
Fig 3. Association between maximal carotid plaque thickness (cPTmax) and carotid artery calcium score (A) and coronary artery calcium score (B).
According to carotid ultrasound findings, patients were divided into 3 groups: No carotid plaques, cPTmax 1.0–1.9 mm, cPTmax >1.9 mm. Based on the distribution of calcium scores from noncontrast CT scanning of the carotid and coronary arteries, patients were divided into calcium score categories of 0, 1–100, 101–400 and >400. The p-values are from cross tabulation and chi-square analysis (rows: Calcium score categories, columns: cPTmax categories).
Fig 4. Association between maximal carotid plaque…
Fig 4. Association between maximal carotid plaque thickness (cPTmax) and carotid artery calcium score in patients with CKD stage 3.
(A) In men versus women, (B) in smokers versus non-smokers, and (C) in patients aged ≤ 64 yrs. versus > 64 yrs. According to carotid ultrasound findings, patients were divided into 3 groups: No carotid plaques, cPTmax 1.0–1.9 mm, cPTmax >1.9 mm. Based on the distribution of calcium scores from CT scanning of the carotid arteries, patients were divided into calcium score categories of 0, 1–100, 101–400 and >400. Non-smokers are defined as patients with 0 smocking pack yrs. and smokers as patients with smoking pack yrs. > 0. Age 64 yrs. is the median age of the CKD patients. The p-values are from cross tabulation and chi-square analysis (rows: Calcium score categories, columns: cPTmax categories).
Fig 5. Association between maximal carotid plaque…
Fig 5. Association between maximal carotid plaque thickness (cPTmax) and thoracic aortic calcium score (A), abdominal aortic calcium score (B) and iliac artery calcium score (C).
According to carotid ultrasound findings, patients were divided into 3 groups: No carotid plaques, cPTmax 1.0–1.9 mm, cPTmax >1.9 mm. Based on the distribution of calcium scores from noncontrast CT scanning of the thoracic aorta, abdominal aorta and iliac arteries, patients were divided into calcium score categories of 0, 1–100, 101–400 and >400. The p-values are from cross tabulation and chi-square analysis (rows: Calcium score categories, columns: cPTmax categories).

References

    1. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al.. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52. doi: 10.1016/S0140-6736(13)60595-4
    1. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2006;151(2):492–500. doi: 10.1016/j.ahj.2005.03.055
    1. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003;64(2):610–5. doi: 10.1046/j.1523-1755.2003.00109.x
    1. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007;18(2):629–36. doi: 10.1681/ASN.2005111204
    1. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al.. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007;18(4):1307–15. doi: 10.1681/ASN.2006101159
    1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–63. doi: 10.1001/archinte.164.6.659
    1. Sosnov J, Lessard D, Goldberg RJ, Yarzebski J, Gore JM. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis. 2006;47(3):378–84. doi: 10.1053/j.ajkd.2005.11.017
    1. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, et al.. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007;50(3):217–24. doi: 10.1016/j.jacc.2007.03.037
    1. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, et al.. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308(8):788–95. doi: 10.1001/jama.2012.9624
    1. Kavousi M, Elias-Smale S, Rutten JH, Leening MJ, Vliegenthart R, Verwoert GC, et al.. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156(6):438–44. doi: 10.7326/0003-4819-156-6-201203200-00006
    1. Baber U, Mehran R, Sartori S, Schoos MM, Sillesen H, Muntendam P, et al.. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. J Am Coll Cardiol. 2015;65(11):1065–74. doi: 10.1016/j.jacc.2015.01.017
    1. Sillesen H, Sartori S, Sandholt B, Baber U, Mehran R, Fuster V. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. Eur Heart J Cardiovasc Imaging. 2018;19(9):1042–50. doi: 10.1093/ehjci/jex239
    1. Matsushita K, Sang Y, Ballew SH, Shlipak M, Katz R, Rosas SE, et al.. Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol. 2015;26(2):439–47. doi: 10.1681/ASN.2014020173
    1. Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, et al.. Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. JAMA Cardiol. 2017;2(6):635–43. doi: 10.1001/jamacardio.2017.0363
    1. Chaikriangkrai K, Nabi F, Mahmarian JJ, Chang SM. Additive prognostic value of coronary artery calcium score and renal function in patients with acute chest pain without known coronary artery disease: up to 5-year follow-up. Int J Cardiovasc Imaging. 2015;31(8):1619–26. doi: 10.1007/s10554-015-0732-9
    1. Lee JH, Rizvi A, Hartaigh BO, Han D, Park MW, Roudsari HM, et al.. The Predictive Value of Coronary Artery Calcium Scoring for Major Adverse Cardiac Events According to Renal Function (from the Coronary Computed Tomography Angiography Evaluation for Clinical Outcomes: An International Multicenter [CONFIRM] Registry). Am J Cardiol. 2019;123(9):1435–42. doi: 10.1016/j.amjcard.2019.01.055
    1. Valdivielso JM, Betriu A, Martinez-Alonso M, Arroyo D, Bermudez-Lopez M, Fernandez E, et al.. Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound. PLoS One. 2017;12(10):e0186665. doi: 10.1371/journal.pone.0186665
    1. Avramovski P, Avramovska M, Sikole A. B-flow imaging estimation of carotid and femoral atherosclerotic plaques: vessel walls rheological damage or strong predictor of cardiovascular mortality in chronic dialysis patients. Int Urol Nephrol. 2016;48(10):1713–20. doi: 10.1007/s11255-016-1393-x
    1. Sorensen IMH, Saurbrey SAK, Hjortkjaer HO, Brainin P, Carlson N, Ballegaard ELF, et al.. Regional distribution and severity of arterial calcification in patients with chronic kidney disease stages 1–5: a cross-sectional study of the Copenhagen chronic kidney disease cohort. BMC Nephrol. 2020;21(1):534. doi: 10.1186/s12882-020-02192-y
    1. Nephrology ISo. KDIGO 2012 Clinical Pratice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements. 2013;3(1):150. doi: 10.1038/kisup.2012
    1. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al.. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12. doi: 10.7326/0003-4819-150-9-200905050-00006
    1. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al.. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(2):93–111; quiz 89–90. doi: 10.1016/j.echo.2007.11.011
    1. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al.. Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23(1):75–80. doi: 10.1159/000097034
    1. Hjortkjaer HO, Jensen T, Hilsted J, Mogensen UM, Rossing P, Kober L, et al.. Generalised arterial calcification in normoalbuminuric patients with type 1 diabetes with and without cardiovascular autonomic neuropathy. Diab Vasc Dis Res. 2019;16(1):98–102. doi: 10.1177/1479164118805904
    1. Erbel R, Mohlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, et al.. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol. 2010;56(17):1397–406. doi: 10.1016/j.jacc.2010.06.030
    1. Arroyo D, Betriu A, Martinez-Alonso M, Vidal T, Valdivielso JM, Fernandez E, et al.. Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study. BMC Nephrol. 2014;15:168. doi: 10.1186/1471-2369-15-168
    1. Coll B, Betriu A, Martinez-Alonso M, Borras M, Craver L, Amoedo ML, et al.. Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: usefulness of non-invasive tests in cardiovascular assessment. Nephrol Dial Transplant. 2010;25(9):3017–25. doi: 10.1093/ndt/gfq109
    1. Hsu S, Rifkin DE, Criqui MH, Suder NC, Garimella P, Ginsberg C, et al.. Relationship of femoral artery ultrasound measures of atherosclerosis with chronic kidney disease. J Vasc Surg. 2018;67(6):1855–63 e1. doi: 10.1016/j.jvs.2017.09.048
    1. Gracia M, Betriu A, Martinez-Alonso M, Arroyo D, Abajo M, Fernandez E, et al.. Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD. Clin J Am Soc Nephrol. 2016;11(2):287–96. doi: 10.2215/CJN.01240215
    1. Kurnatowska I, Grzelak P, Stefanczyk L, Nowicki M. Tight relations between coronary calcification and atherosclerotic lesions in the carotid artery in chronic dialysis patients. Nephrology (Carlton). 2010;15(2):184–9. doi: 10.1111/j.1440-1797.2009.01169.x

Source: PubMed

3
Subscribe